BioSpace News Archive

vTv Therapeutics said that the funds it saves through this process will allow it to focus on the Phase III development of TP399 and the company’s future growth.

The Cambridge, Massachusetts-based company has developed an artificial intelligence platform designed to optimize pharmaceutical formulation processes.

Physician-scientists from Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility, will present expansive new hematology/oncology data from their clinical research program at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, being held in Atlanta, Georgia (and virtually) from December 11-14, 2021.

Can-Fite BioPharma Ltd today announced the last of approximately 400 psoriasis patients enrolled in its Phase III Comfort™ study is scheduled to complete a 16-week cycle of treatment with Piclidenoson, the Company’s lead drug candidate, at the beginning of January 2022.

Aurora Spine Corporation announced today that it will be participating in the Lytham Partners Winter 2021 Investor Conference taking place from December 13-16, 2021.

Capsida Biotherapeutics Inc. today announced the appointment of Peter Anastasiou as the company’s Chief Executive Officer (CEO) and the promotions of Capsida co-founders Nicholas Flytzanis, Ph.D., to Chief Scientific Officer (CSO) and Nick Goeden, Ph.D., to Chief Technology Officer (CTO).

Innovation Pharmaceuticals today provides shareholders with perspectives on the Company’s go-forward strategy heading into 2022.

Cyprium Therapeutics, Inc. (“Cyprium”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) partner company, with support from its licensing partner Sentynl Therapeutics, Inc. (“Sentynl”), a wholly owned subsidiary of Cadila Healthcare Limited (“Zydus”), today announced the initiation of a rolling submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for CUTX-101 (“Copper Histidinate”) for the treatment of Menkes disease.

Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the Company developing new classes of synthetic anti-infectives, is pleased to provide an update on its Phase I/II clinical trial for the treatment of burn wound infections.

Clover Biopharmaceuticals, Ltd. announced that they have entered into a long-term agreement with UNICEF for Clover to supply its COVID-19 vaccine candidate, SCB-2019, to the COVAX Facility.